Results 121 to 130 of about 79,283 (266)

Repurposing the MEK inhibitor binimetinib as a dual anti-inflammatory and antifibrotic agent in pulmonary fibrosis. [PDF]

J Thorac Dis
Zhang Y, Chen Q, Shi Y, Li Z, Chen R, Wang M, Shao C, Gao S, Zhou H, Huang H.   +9 more
europepmc   +1 more source

Downregulation of KRTAP2‐3 Suppresses Proliferation and Tumor Formation of Oral Cancer Cells via Inactivation of KRAS Signals

Cancer Science, EarlyView.
KRTAP2‐3 drives OSCC progression by sustaining both mesenchymal and proliferative properties through KRAS signaling. Loss of KRTAP2‐3 induces MET, suppresses KRAS pathway activation, and markedly reduces tumor cell proiferation and tumor formation as illustarted in Figure.
Qianqian Miao, Zhijun Huang, Kazuki Takahashi, Haruka Ibi, Kohei Miyazono, Katarzyna A. Podyma‐Inoue, Tetsuro Watabe   +6 more
wiley   +1 more source

AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma. [PDF]

Neoplasia
Paudel R, Goller S, Schwarz S, Meder K, Goebeler M, Schmidt M.   +5 more
europepmc   +1 more source

Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3

Cancer Science, EarlyView.
Oncogenic BRAF and KRAS promote global DNA hypomethylation through a directed pathway that increases the levels of TET3, which helps drive tumorigenesis. ABSTRACT Aberrant epigenetic modification is one of the characteristics of the cancer genome.
Ichiro Onoyama, W. Rod Hardy, Shoichiro Takeishi, Lihua Julie Zhu, Yanglan Tan, Lloyd Hutchinson, Jianhong Ou, Leyuan Ma, Ching‐Man Virbasius, Masafumi Yasunaga, Keiichi I. Nakayama, Scott A. Shaffer, Michael R. Green   +12 more
wiley   +1 more source

MEK inhibitor mirdametinib promotes fracture healing in osteofibrous dysplasia RASopathy. [PDF]

J Clin Invest
Khalid AB, Denton K, Paria N, Oxendine I, Wassell M, Cornelia R, Uppuganti S, Nyman JS, Jagadeesh GJ, Ferreira CR, Conway SJ, Hammer RE, Ritter J, Nguyen M, Podeszwa DA, Klesse LJ, Wise CA, Rios JJ.   +17 more
europepmc   +1 more source

MEK Inhibitor AZD8330 [PDF]

, 2020
openaire   +1 more source

Combined MEK1/2 and Autophagy Inhibition Suppresses Tumor Growth via STING‐Mediated Type I Interferon Response in iCCA

Cancer Science, EarlyView.
Through bioinformatic analyses, iCCA cell models, and in vivo xenograft experiments, we show that autophagy inhibition sensitizes iCCA to MEK1/2 blockade by enhancing STING‐dependent type I interferon signaling. These findings support combined MEK1/2 and autophagy inhibition as a promising therapeutic strategy for iCCA. ABSTRACT The RAF–MEK–ERK pathway
Chengqiang Sun, Zheng Gao, Enfu Dong, Liangxia Ding, Shanru Feng, Jiafeng Chen, Pascal Kwangwari, Yinghong Shi, Weiren Liu, Xin Zhang, Ao Huang, Jian Zhou, Sheng Wang, Jia Fan, Xiutao Fu, ZhenBin Ding   +15 more
wiley   +1 more source

Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells. [PDF]

J Proteome Res
Simiczyjew A, Surman M, Kot M, Przybyło ME, Nowak D.   +4 more
europepmc   +1 more source

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development

Cancer Science, EarlyView.
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura, Minji Jo, Motoko Takahashi, Toru Hirota   +3 more
wiley   +1 more source

Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma. [PDF]

Oncogenesis
Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H.   +5 more
europepmc   +1 more source